Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its lead product candidate, roluperidone, is being developed for the treatment of negative symptoms of schizophrenia. The company received a Complete Response Letter from the FDA in February 2024 for its NDA for roluperidone and is planning a confirmatory Phase 3 trial (C19).
Q2 FY2026 — expected 2026-09-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-11 | 2025-12-31 | 0001193125-26-101117 | EDGAR | 82K words |
| 2025-02-25 | 2024-12-31 | 0000950170-25-026055 | EDGAR | 79K words |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018392 | EDGAR | 80K words |
| 2023-03-08 | 2022-12-31 | 0000950170-23-006577 | EDGAR | 79K words |
| 2022-03-01 | 2021-12-31 | 0001564590-22-007853 | EDGAR | — |
| 2021-03-08 | 2020-12-31 | 0001564590-21-011340 | EDGAR | — |
| 2020-03-09 | 2019-12-31 | 0001564590-20-009243 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001564590-19-007246 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001564590-18-005224 | EDGAR | — |
| 2017-03-13 | 2016-12-31 | 0001564590-17-004048 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-07 | 2026-06-30 | 0001193125-26-339171 | EDGAR | 23K words |
| 2025-11-05 | 2025-09-30 | 0001193125-25-265685 | EDGAR | 20K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108840 | EDGAR | 19K words |
| 2025-05-13 | 2025-03-31 | 0000950170-25-069780 | EDGAR | 16K words |
| 2024-11-05 | 2024-09-30 | 0000950170-24-121063 | EDGAR | 20K words |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091195 | EDGAR | 19K words |
| 2024-05-01 | 2024-03-31 | 0000950170-24-050883 | EDGAR | 18K words |
| 2023-11-07 | 2023-09-30 | 0000950170-23-059747 | EDGAR | 28K words |
| 2023-08-01 | 2023-06-30 | 0000950170-23-036159 | EDGAR | 27K words |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021947 | EDGAR | 22K words |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023496 | EDGAR | 20K words |
| 2022-08-09 | 2022-06-30 | 0000950170-22-015754 | EDGAR | 20K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-12 | 0001193125-26-346817 | EDGAR | 1K words |
| 2026-08-07 | 0001193125-26-339147 | EDGAR | 4K words |
| 2026-04-06 | 0001193125-26-143986 | EDGAR | 1K words |
| 2026-04-02 | 0001193125-26-140148 | EDGAR | 1K words |
| 2026-03-11 | 0001193125-26-101074 | EDGAR | 5K words |
| 2026-02-03 | 0001193125-26-034538 | EDGAR | 1K words |
| 2025-12-22 | 0001193125-25-328715 | EDGAR | 16K words |
| 2025-11-19 | 0001193125-25-287048 | EDGAR | 1K words |
| 2025-10-22 | 0001193125-25-245552 | EDGAR | 2K words |
| 2025-03-19 | 0001193125-25-057901 | EDGAR | 1K words |
207 total filings indexed. 175 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001598646 |
| Ticker | NERV |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | MA |
| Website | https://www.minervaneurosciences.com |
| Listed | 2014-07-01 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NERV (~200 tokens, structured JSON with cryptographic provenance)